<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699296</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589B1201</org_study_id>
    <nct_id>NCT00699296</nct_id>
  </id_info>
  <brief_title>Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma</brief_title>
  <official_title>A Phase II Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese
      adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma.
      LBH589 is administered orally once a day for three days per week.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response (CR/PR) rate by using the modified Severity-Weighted Assessment Tool (mSWAT) to assess skin disease and the combined evaluation of disease in the viscera/lymph nodes, peripheral blood and bone marrow</measure>
    <time_frame>Every Cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate using mSWAT Response rate using the Physician's Global Assessment of Clinical Condition (PGA) Responses in index lesions by skin lesion measurements and with photographic supporting documentation Overall response(CR/PR) rate by using PG</measure>
    <time_frame>1 cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <condition>Leukemia-Lymphoma, Adult T-Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat (LBH589)</intervention_name>
    <description>20mg/day p.o. on three times-a- week</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  CTCL: Biopsy-confirmed MF or SS stages IB-IVA2.

          -  Patients who have SS with bone marrow involvement are also eligible.

          -  Patients with transformed CTCL are eligible.

          -  ATL: Patient with cytologically or histopathologically confirmed lymphoma.

          -  Lymphoma should be identified as tumors derived peripheral T-cells by cell surface
             marker.

          -  ATL: Patients with positivity for anti-HTLV-1 antibody

          -  Patients must have received at least two systemic therapy regimens.

          -  Patients must have had disease progression on or following their most recent treatment
             regimen.

          -  Age ≥ 20 years

          -  ECOG Performance Status of ≤ 2

          -  Written informed consent obtained prior to any study specific screening procedures

        Exclusion criteria:

          -  Patients with a history of primary CNS tumors

          -  Any history or presence of brain metastases

          -  Patients with any peripheral neuropathy ≥ CTCAE grade 2

          -  Patients with unresolved diarrhea &gt; CTCAE grade 1

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral LBH589

          -  Patients with concurrent severe and/or uncontrolled liver or renal disease

          -  Patients using sodium valproate ≤5 days prior to starting study drug

          -  Patients with an active bleeding diathesis or on any treatment with therapeutic doses
             of sodium warfarin or other antivitamin K drugs

          -  Patients who have received any investigational drug or chemotherapy or undergone major
             surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side
             effects of such therapy

          -  Patients who have received biologic therapy, target therapy (e.g. denileukin diftitix
             ), vaccine, systemic steroids or immunotherapy ≤ 2 weeks prior to starting study
             treatment or who have not recovered from side effects of such therapy

          -  Patients who have received wide field radiotherapy ≤ 4 weeks or limited field
             radiation for palliation ≤ 2 weeks prior to starting study drug or who have not
             recovered from side effects of such therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makoto Sugaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Tokyo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenji Iwatsuki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Okayama University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshiki Tokura</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Occupational and Environmental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kunihiro Tsukasaki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nagasaki University Hospital of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hironobu In</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kumamoto University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitsuru Setoyama</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miyazaki Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atae Utsunomiya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imamura Bun-in Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Occupational and Environmental Health</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imamura Bun-in Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital of Medicine and Dentistry</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LBH589</keyword>
  <keyword>HDAC inhibitor</keyword>
  <keyword>cutaneous T-ceII lymphoma</keyword>
  <keyword>adult T-cell leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

